GRI Bio issued grant from Korean Intellectual Property Office

GRI Bio announced that the Korean Intellectual Property Office has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, “Prevention and Treatment of Inflammatory Conditions.” The issued patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT cells in the prevention and treatment of inflammatory conditions of the liver. More specifically, when issued the patent will cover the prevention and treatment of inflammatory and fibrotic conditions through the administration of a Retinoic Acid Receptor agonist that inhibits iNKT cells and the administration of an RAR agonist that inhibits the activity of iNKT cells in a subject. “We are pleased to add this Korea patent to our intellectual property portfolio covering our innovative pipeline of NKT cell modulators. Each granted patent provides further validation and bolsters our confidence of our differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases. As we continue to advance our development programs forward, we remain steadfast in our commitment to expand our IP globally and position the Company to address the global unmet need amongst patients for much needed treatment options,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.